These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

569 related items for PubMed ID: 27436085

  • 1. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
    Terlikowska KM, Dobrzycka B, Witkowska AM, Mackowiak-Matejczyk B, Sledziewski TK, Kinalski M, Terlikowski SJ.
    J Ovarian Res; 2016 Jul 19; 9(1):43. PubMed ID: 27436085
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
    Suri A, Perumal V, Ammalli P, Suryan V, Bansal SK.
    Sci Rep; 2021 Aug 27; 11(1):17308. PubMed ID: 34453074
    [Abstract] [Full Text] [Related]

  • 3. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, Peiretti M, Radice D, Passerini R, Sideri M.
    Gynecol Oncol; 2013 Feb 27; 128(2):233-8. PubMed ID: 23200911
    [Abstract] [Full Text] [Related]

  • 4. Proofs for implementation of higher HE4 and ROMA index cut-off values in ovarian cancer preoperative stratification.
    Špacir Prskalo Z, Bulić P, Langer S, Gaće M, Puljiz M, Danolić D, Alvir I, Mamić I, Šušnjar L, Mayer L.
    J Obstet Gynaecol; 2019 Feb 27; 39(2):195-201. PubMed ID: 30207507
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.
    Gynecol Oncol; 2012 Nov 27; 127(2):379-83. PubMed ID: 22835718
    [Abstract] [Full Text] [Related]

  • 6. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M, Stieber P, Hertlein L, Kirschenhofer A, Fürst S, Mayr D, Nagel D, Hofmann K, Krocker K, Burges A.
    Clin Chem Lab Med; 2011 Sep 16; 49(12):2081-8. PubMed ID: 21923475
    [Abstract] [Full Text] [Related]

  • 7. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C, Leon AE, Fabricio ASC, Taborelli M, Polesel J, Del Pup L, Steffan A, Cervo S, Ravaggi A, Zanotti L, Bandiera E, Odicino FE, Scattolo N, Squarcina E, Papadakis C, Maggino T, Gion M.
    Gynecol Oncol; 2016 May 16; 141(2):303-311. PubMed ID: 26801941
    [Abstract] [Full Text] [Related]

  • 8. [Evaluation of applicability of HE4 and ROMA in the preoperative diagnosis of adnexal masses].
    Janas L, Głowacka E, Wilczyński JR, Malinowski A, Nowak M.
    Ginekol Pol; 2015 Mar 16; 86(3):193-7. PubMed ID: 25920309
    [Abstract] [Full Text] [Related]

  • 9. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
    Chen X, Zhou H, Chen R, He J, Wang Y, Huang L, Sun L, Duan C, Luo X, Yan H.
    Clin Chim Acta; 2015 Feb 02; 440():57-63. PubMed ID: 25447698
    [Abstract] [Full Text] [Related]

  • 10. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
    Wang Q, Wu Y, Zhang H, Yang K, Tong Y, Chen L, Zhou Q, Guan S.
    Clin Lab; 2019 Apr 01; 65(4):. PubMed ID: 30969083
    [Abstract] [Full Text] [Related]

  • 11. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.
    Ortiz-Muñoz B, Aznar-Oroval E, García García A, Covisa Peris A, Perez Ballestero P, Sanchez Yepes M, Garcia Lozano T, Illueca Ballester C, García Garcia E.
    Tumour Biol; 2014 Jul 01; 35(7):7249-58. PubMed ID: 24771264
    [Abstract] [Full Text] [Related]

  • 12. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL, Wang CJ, Qi P, Zhang YX.
    Clin Transl Oncol; 2017 Oct 01; 19(10):1260-1267. PubMed ID: 28444641
    [Abstract] [Full Text] [Related]

  • 13. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China.
    Xu Y, Zhong R, He J, Ding R, Lin H, Deng Y, Zhou L, Li X, Jiang J, Bao Y, Luo X, Duan C.
    Clin Biochem; 2016 Jan 01; 49(1-2):32-40. PubMed ID: 26285075
    [Abstract] [Full Text] [Related]

  • 14. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
    Zhang L, Chen Y, Wang K.
    Curr Probl Cancer; 2019 Apr 01; 43(2):135-144. PubMed ID: 30017407
    [Abstract] [Full Text] [Related]

  • 15. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
    Dayyani F, Uhlig S, Colson B, Simon K, Rolny V, Morgenstern D, Schlumbrecht M.
    Int J Gynecol Cancer; 2016 Nov 01; 26(9):1586-1593. PubMed ID: 27540691
    [Abstract] [Full Text] [Related]

  • 16. Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers.
    Yanaranop M, Jantarateptewan N, Tiyayon J, Nakrangsee S.
    Int J Gynecol Cancer; 2018 Jul 01; 28(6):1058-1065. PubMed ID: 29975290
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
    Hada A, Han LP, Chen Y, Hu QH, Yuan Y, Liu L.
    J Ovarian Res; 2020 Apr 25; 13(1):46. PubMed ID: 32334618
    [Abstract] [Full Text] [Related]

  • 18. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.
    Chan KK, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Sumpaico WW.
    Gynecol Oncol; 2013 Feb 25; 128(2):239-44. PubMed ID: 23063998
    [Abstract] [Full Text] [Related]

  • 19. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M, Kristjansdottir B, Sundfeldt K.
    Gynecol Oncol; 2018 Oct 25; 151(1):159-165. PubMed ID: 30149898
    [Abstract] [Full Text] [Related]

  • 20. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
    Shipeng G, Yongning C, Yadi Z, Chanyuan LI, Qifan J.
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec 30; 39(12):1393-1401. PubMed ID: 31907150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.